BioStem Technologies ((BSEM)) announced an update on their ongoing clinical study.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
BioStem Technologies is conducting a clinical study titled ‘A Prospective, Multicenter, Randomized, Controlled Trial of Non-healing Venous Leg Ulcers Treated With Standard Care With or Without BR-AC.’ The study aims to evaluate the effectiveness of the BR-AC treatment in promoting healing in venous leg ulcers compared to standard care alone. The significance of this study lies in its potential to improve treatment outcomes for patients with chronic wounds.
The intervention being tested is the BioREtain® Amnion Chorion (BR-AC), a human placental allograft. BR-AC is designed to enhance wound healing when applied to non-healing venous leg ulcers, potentially leading to complete wound closure within 12 weeks.
This study follows an interventional design with randomized allocation and a parallel intervention model. It employs single masking to ensure unbiased assessment of wound closure. The primary purpose is to evaluate the treatment efficacy of BR-AC in venous leg ulcers.
The study began on February 14, 2025, with the latest update submitted on June 23, 2025. These dates are crucial as they mark the progression of the study and its ongoing recruitment status.
The market implications of this study are significant for BioStem Technologies, as positive results could enhance their stock performance and attract investor interest. The study’s outcome could also impact the competitive landscape in the wound care industry, influencing strategies of other companies in the sector.
The study is currently ongoing, with further details available on the ClinicalTrials portal.